

Amendments to the Specification:

Please note: to distinguish text passages which were already underlined, additions to the text are marked with double underlines.

Please replace the paragraph at page 9, from line 17 through line 30, with the following paragraph:

--The molecule may be a fusion polypeptide which comprises one or more amino acids interposed between the first and second parts which bind to cells, e.g. a fusion polypeptide which comprises a first amino acid sequence which can bind to an antigen bearing target and a second amino acid sequence which can bind to a leukocyte, and which further comprises at least one amino acid interposed between the first and second parts. The interposed amino acids may comprise, e.g., a linker sequence intended to lessen steric hindrance or other undesirable interactions between the aforementioned first and second parts. For, example, one such type of sequence takes the form $(\text{Gly}_3\text{Ser})_n$. Additional useful linkers include, but are not limited to $(\text{Arg-Ala-Arg-Asp-Pro-Arg-Val-Pro-Val-Ala-Thr})_{1-5}$ (SEQ ID NO:1) (Xu et al., 1999, Proc. Natl. Acad. Sci. U.S.A. 96: 151-156), $(\text{Gly-Ser})_n$ (Shao et al., 2000, Bioconjug. Chem. 11: 822-826), $(\text{Thr-Ser-Pro})_n$ (Kroon et al., 2000, Eur. J. Biochem. 267: 6740-6752), $(\text{Gly-Gly-Gly})_n$ (Kluczyk et al., 2000, Peptides 21: 1411-1420), and $(\text{Glu-Lys})_n$ (Kluczyk et al., 2000, supra), wherein n is 1 to 15 (each of the preceding references is also incorporated herein by reference). In another embodiment, no amino acids are interposed between the first and second parts. --

Please replace the paragraph at page 79, from line 14 through line 20, with the following paragraph:

--At the nucleotide level the human and the murine IL4 gene display approximately 70% homology. The 5' region of the IL4 contains several sequence elements, designated CLE (conserved lymphokine element), that are binding sites for transcription factors controlling the expression of this and other genes. A sequence motif, called P sequence (CGAAAATTTC; ~~SEQ ID NO:1~~ SEQ ID NO:2) in the 5' region of the human IL4 gene (positions -79 - - 69) is the binding site for a nuclear factor, called NF(P), mediating the response to T-cell activation signals.--

Please replace the line at page 167, line 2, with the following line:

--GTX-5 (SEQ ID NO:3)--

Please replace the line at page 167, line 12, with the following line:

--GTX-6 (SEQ ID NO:4)--

Please replace the line at page 168, line 15, with the following line:

--Upstream (SEQ ID NO:5)--

Please replace the line at page 168, line 17, with the following line:

--Downstream (SEQ ID NO:6)--

Please replace the line at page 169, line 14, with the following line:

--Upstream Primer (SEQ ID NO:7)--

Please replace the line at page 169, line 15, with the following line:

--Downstream (SEQ ID NO:8) --

Please replace the line at page 170, line 18, with the following line:

--Upstream (SEQ ID NO:9) --

Please replace the line at page 170, line 19, with the following line:

--Downstream (SEQ ID NO:10) --

Please replace the line at page 178, line 10, with the following line:

--Upstream (SEQ ID NO:11) --

Please replace the line at page 178, line 12, with the following line:

--Downstream (SEQ ID NO:12) --

Please replace the paragraph at page 179, from line 13 through line 14, with the following paragraph:

--(SEQ ID NO:13) 5'TACGGCCGGCACCCGCCCCGCTCGCCCAGCCCC
(SEQ ID NO:14) 3'TACGGCCGCCACAATGAAAATAAGATACCAT --

Please replace the paragraph at page 180, from line 19 through line 20, with the following paragraph:

--(SEQ ID NO:15) 5' CCGGCACTAGTGGCGGAGGGGGCTCCGGCGGCGGGGGCAGCG
(SEQ ID NO:16) 5' CTAGCGCTGCCCCCGCCGCCGGCGCCCCCTCCGCCACTAGTG --

Please replace the paragraph at page 180, from line 24 through line 25, and continuing to page 181, lines 1 - 2, with the following paragraph:

-- 3. DNA sequence coding for the peptide GGGGSGGGGS (SEQ ID NO:17) where G stands for glycine and S stands for serine. This 10 amino acid sequence (G₄S)₂ is designed to insert a kink/spacer in the protein between the GMCSF and the Gas1.1 moieties.--

Please replace the line at page 181, line 27, with the following line:

--Upstream HA1 Primer (SEQ ID NO:18) --

Please replace the line at page 182, line 2, with the following line:

--Downstream HA1 Primer (SEQ ID NO:19) --

Please replace the line at page 182, line 22, with the following line:

-- Upstream Primer (SEQ ID NO:20) --

Please replace the line at page 182, line 24, with the following line:

--Downstream Primer (SEQ ID NO:21) --

Please replace the line at page 185, line 11, with the following line:

--Upstream Primer (SEQ ID NO:22) --

Please replace the line at page 185, line 13, with the following line:

--Downstream Primer (SEQ ID NO:23) --

Please replace the line at page 186, line 11, with the following line:

--Upstream Primer (SEQ ID NO:24) --

Please replace the line at page 186, line 13, with the following line:

--Downstream Primer (SEQ ID NO:25) --

Please replace the line at page 187, line 13, with the following line:

--Upstream Primer (SEQ ID NO:26) --

Please replace the line at page 187, line 15, with the following line:

--Downstream Primer (SEQ ID NO:27) --

Please replace the line at page 192, line 22, with the following line:

-- Upstream hGM-CSF Primer (SEQ ID NO:28) --

Please replace the line at page 192, line 24, with the following line:

-- Downstream hGM-CSF Primer (SEQ ID NO:29) --

Please replace the line at page 193, line 16, with the following line:


--Upstream Primer (SEQ ID NO:30) --

Please replace the line at page 193, line 18, with the following line:

--Downstream Primer (SEQ ID NO:31) --

Date: 3/8/04

Respectfully submitted,


Name: Kathleen Williams

Registration No.: 34,380

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

Matthew Beaudet
50,649; signing for: